Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESRRB | O95718 | 4/20 | 0.49 |
| ▸ | ESRRA | P11474 | 4/20 | 0.49 |
| ▸ | PRF1 | P14222 | 2/20 | 0.39 |
| ▸ | ESR1 | P03372 | 7/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 6/20 | 0.38 |
| ▸ | MMP3 | P08254 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | MIF | P14174 | 1/20 | 0.36 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.35 |
| ▸ | WEE1 | P30291 | 1/20 | 0.35 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.33 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA3 | P07451 | 1/20 | 0.33 |
| ▸ | CA6 | P23280 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3190566 | 0.86 | ESRRB (0.47) | ESRRBESRRAESR1ESR2MIF | |
| SCHEMBL3198412 | 0.86 | ESRRB (0.36) | ESRRBESRRAESR1ESR2MMP3 | |
| SCHEMBL3203612 | 0.85 | ESR1 (0.40) | ESRRBESRRAESR1ESR2MAOA | |
| SCHEMBL3185517 | 0.85 | ESR1 (0.40) | ESRRBESRRAESR1ESR2MAOA | |
| SCHEMBL3188483 | 0.84 | ALOX5 (0.39) | ESRRBESRRAPRF1ESR1ESR2 | |
| SCHEMBL3201465 | 0.82 | PIK3CA (0.39) | ESRRBESRRAPRF1ESR1ESR2 | |
| SCHEMBL3200415 | 0.82 | ESR1 (0.43) | ESRRBESRRAESR1ESR2MAOA | |
| SCHEMBL3195435 | 0.82 | ESRRB (0.39) | ESRRBESRRAPRF1ESR1ESR2 | |
| SCHEMBL3190395 | 0.82 | GPR84 (0.38) | ESRRBESRRAPRF1ESR1ESR2 | |
| SCHEMBL3178841 | 0.82 | ESRRB (0.49) | ESRRBESRRAPRF1ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7157492-B2 | Dibenzo chromene derivatives and their use as ERβ selective ligands | WYETH (US) | 2007-01-02 | — | — | US | claimed |
| EP-1718630-A1 | DIBENZO CHROMENE DERIVATIVES AND THEIR USE AS ER&bgr; SELECTIVE LIGANDS | Wyeth a Corporation of the State of Delaware (US) | 2006-11-08 | — | — | EP | claimed |
| US-20050234074-A1 | Dibenzo chromene derivatives and their use as ERbeta selective ligands | WYETH (US) | 2005-10-20 | — | — | US | claimed |
| WO-2005082880-A1 | DIBENZO CHROMENE DERIVATIVES AND THEIR USE AS ERβ SELECTIVE LIGANDS | WYETH (US) | 2005-09-09 | — | — | WO | claimed |
| US-7671084-B2 | Dibenzo chromene derivatives and their use as ERβ selective ligands | WYETH (US) | 2010-03-02 | — | — | US | disclosed |
| US-20070049605-A1 | Dibenzo chromene derivatives and their use as ERbeta selective ligands | WYETH (US) | 2007-03-01 | — | — | US | disclosed |
| US-7157492-B2 | Dibenzo chromene derivatives and their use as ERβ selective ligands | WYETH (US) | 2007-01-02 | — | — | US | disclosed |
| EP-1718630-A1 | DIBENZO CHROMENE DERIVATIVES AND THEIR USE AS ER&bgr; SELECTIVE LIGANDS | Wyeth a Corporation of the State of Delaware (US) | 2006-11-08 | — | — | EP | disclosed |
| US-20050234074-A1 | Dibenzo chromene derivatives and their use as ERbeta selective ligands | WYETH (US) | 2005-10-20 | — | — | US | disclosed |
| WO-2005082880-A1 | DIBENZO CHROMENE DERIVATIVES AND THEIR USE AS ERβ SELECTIVE LIGANDS | WYETH (US) | 2005-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234074-A1 | Dibenzo chromene derivatives and their use as ERbeta selective ligands | ESR2, ESR1, ESRRB | ESRRB 3/4885ESRRA 4/4885PRF1 4438/4885 |
| US-20070049605-A1 | Dibenzo chromene derivatives and their use as ERbeta selective ligands | ESR2, ESR1, ESRRA | ESRRB 4/4885ESRRA 3/4885PRF1 4486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.